Literature DB >> 9751528

A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro.

J M Quinn1, J Elliott, M T Gillespie, T J Martin.   

Abstract

Both human and murine osteoclasts can be derived in vitro from hematopoietic cells or monocytes that are co-cultured with osteoblasts or marrow-derived stromal cells. The osteoclastogenic stimulus provided by murine osteoblasts and marrow-derived stromal cells is now known to be mediated by osteoclast differentiation factor (ODF), a membrane-bound tumor necrosis factor-related ligand. This study demonstrates that mouse spleen cells and monocytes form osteoclasts when cultured in the presence of macrophage-colony stimulating factor (M-CSF) and a soluble form of murine ODF (sODF). Numerous multinucleated osteoclasts expressing tartrate resistant acid phosphatase (TRAP) and calcitonin receptor (CTR) formed within 7 days of culture and engaged in extensive lacunar bone resorption. Osteoclast number and bone resorption area was dependent on sODF concentration. Long-term cultured human monocytes also formed bone resorbing osteoclasts in response to co-stimulation by sODF and M-CSF, although this required more than 11 days in culture. This human osteoclast differentiation was strongly inhibited by granulocyte-macrophage colony stimulating factor. This study further characterises murine osteoclast differentiation caused by sODF and M-CSF co-stimulation in vitro, and shows that the same co-stimulation causes human osteoclast differentiation to occur. We propose that this methodology can be employed to investigate the direct effects of cytokines and other factors on human osteoclast differentiation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9751528     DOI: 10.1210/endo.139.10.6331

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  78 in total

1.  RANKing the importance of measles virus in Paget's disease.

Authors:  F P Ross
Journal:  J Clin Invest       Date:  2000-03       Impact factor: 14.808

Review 2.  Pathogenesis of postmenopausal osteoporosis.

Authors:  L G Raisz
Journal:  Rev Endocr Metab Disord       Date:  2001-01       Impact factor: 6.514

Review 3.  Hypercalcemia of malignancy.

Authors:  V Grill; T J Martin
Journal:  Rev Endocr Metab Disord       Date:  2000-11       Impact factor: 6.514

4.  Alteration of the RANKL/RANK/OPG System in Periprosthetic Osteolysis with Septic Loosening.

Authors:  Long Wang; Zixun Dai; Jie Xie; Hao Liao; Cheng Lv; Yihe Hu
Journal:  Inflammation       Date:  2016-02       Impact factor: 4.092

5.  Myeloid-derived suppressor cells contribute to bone erosion in collagen-induced arthritis by differentiating to osteoclasts.

Authors:  Hui Zhang; Yuefang Huang; Shuang Wang; Rong Fu; Chaohuan Guo; Hongyue Wang; Jijun Zhao; Felicia Gaskin; Jingxian Chen; Niansheng Yang; Shu Man Fu
Journal:  J Autoimmun       Date:  2015-08-28       Impact factor: 7.094

Review 6.  Osteoclasts: New Insights.

Authors:  Xu Feng; Steven L Teitelbaum
Journal:  Bone Res       Date:  2013-03-29       Impact factor: 13.567

7.  Mutation in Osteoactivin Promotes Receptor Activator of NFκB Ligand (RANKL)-mediated Osteoclast Differentiation and Survival but Inhibits Osteoclast Function.

Authors:  Samir M Abdelmagid; Gregory R Sondag; Fouad M Moussa; Joyce Y Belcher; Bing Yu; Hilary Stinnett; Kimberly Novak; Thomas Mbimba; Matthew Khol; Kurt D Hankenson; Christopher Malcuit; Fayez F Safadi
Journal:  J Biol Chem       Date:  2015-04-02       Impact factor: 5.157

8.  Cloning and characterization of osteoclast precursors from the RAW264.7 cell line.

Authors:  Bethany L V Cuetara; Tania N Crotti; Anthony J O'Donoghue; Kevin P McHugh
Journal:  In Vitro Cell Dev Biol Anim       Date:  2006 Jul-Aug       Impact factor: 2.416

9.  Improved methods for testing antiresorptive compounds in human osteoclast cultures.

Authors:  Jukka P Rissanen; Hannele Ylipahkala; Katja M Fagerlund; Clive Long; H Kalervo Väänänen; Jussi M Halleen
Journal:  J Bone Miner Metab       Date:  2008-11-19       Impact factor: 2.626

10.  Interleukin-32 promotes osteoclast differentiation but not osteoclast activation.

Authors:  Guillaume Mabilleau; Afsie Sabokbar
Journal:  PLoS One       Date:  2009-01-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.